Healthcare resource use and costs of multiple sclerosis patients in Germany before and during fampridine treatment
Abstract Background Multiple sclerosis (MS) patients often suffer from gait impairment and fampridine is indicated to medically improve walking ability in this population. Patient characteristics, healthcare resource use, and costs of MS patients on fampridine treatment for 12 months in Germany were...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2017-03-01
|
| Series: | BMC Neurology |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s12883-017-0844-z |
| _version_ | 1818421689585762304 |
|---|---|
| author | Tjalf Ziemssen Christine Prosser Jennifer Scarlet Haas Andrew Lee Sebastian Braun Pamela Landsman-Blumberg Angela Kempel Erika Gleißner Sarita Patel Ming-Yi Huang |
| author_facet | Tjalf Ziemssen Christine Prosser Jennifer Scarlet Haas Andrew Lee Sebastian Braun Pamela Landsman-Blumberg Angela Kempel Erika Gleißner Sarita Patel Ming-Yi Huang |
| author_sort | Tjalf Ziemssen |
| collection | DOAJ |
| description | Abstract Background Multiple sclerosis (MS) patients often suffer from gait impairment and fampridine is indicated to medically improve walking ability in this population. Patient characteristics, healthcare resource use, and costs of MS patients on fampridine treatment for 12 months in Germany were analyzed. Methods A retrospective claims database analysis was conducted including MS patients who initiated fampridine treatment (index date) between July 2011 and December 2013. Continuous insurance enrollment during 12 months pre- and post-index date was required, as was at least 1 additional fampridine prescription in the fourth quarter after the index date. Patient characteristics were evaluated and pre- vs post-index MS-related healthcare utilization and costs were compared. Results A total of 562 patients were included in this study. The mean (standard deviation [SD]) age was 50.5 (9.8) years and 63% were female. In the treatment period, almost every patient had at least 1 MS-related outpatient visit, 24% were hospitalized due to MS, and 79% utilized MS-specific physical therapy in addition to the fampridine treatment. Total MS-related healthcare costs were significantly higher in the fampridine treatment period than in the period prior to fampridine initiation (€17,392 vs €10,960, P < 0.001). While this difference was driven primarily by prescription costs, MS-related inpatient costs were lower during fampridine treatment (€1,333 vs €1,565, P < 0.001). Conclusions Physical therapy is mainly used concomitant to fampridine treatment. While healthcare costs were higher during fampridine treatment compared to the pre-treatment period, inpatient costs were lower. Further research is necessary to better understand the fampridine influence. |
| first_indexed | 2024-12-14T13:14:21Z |
| format | Article |
| id | doaj.art-72e5e06b669643a6ae2720b87e33d33f |
| institution | Directory Open Access Journal |
| issn | 1471-2377 |
| language | English |
| last_indexed | 2024-12-14T13:14:21Z |
| publishDate | 2017-03-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Neurology |
| spelling | doaj.art-72e5e06b669643a6ae2720b87e33d33f2022-12-21T23:00:06ZengBMCBMC Neurology1471-23772017-03-011711910.1186/s12883-017-0844-zHealthcare resource use and costs of multiple sclerosis patients in Germany before and during fampridine treatmentTjalf Ziemssen0Christine Prosser1Jennifer Scarlet Haas2Andrew Lee3Sebastian Braun4Pamela Landsman-Blumberg5Angela Kempel6Erika Gleißner7Sarita Patel8Ming-Yi Huang9Universitätsklinium DresdenXcenda GmbHXcenda GmbHBiogenXcenda GmbHXcenda LLCBiogen GmbHBiogen GmbHBiogen GmbHBiogenAbstract Background Multiple sclerosis (MS) patients often suffer from gait impairment and fampridine is indicated to medically improve walking ability in this population. Patient characteristics, healthcare resource use, and costs of MS patients on fampridine treatment for 12 months in Germany were analyzed. Methods A retrospective claims database analysis was conducted including MS patients who initiated fampridine treatment (index date) between July 2011 and December 2013. Continuous insurance enrollment during 12 months pre- and post-index date was required, as was at least 1 additional fampridine prescription in the fourth quarter after the index date. Patient characteristics were evaluated and pre- vs post-index MS-related healthcare utilization and costs were compared. Results A total of 562 patients were included in this study. The mean (standard deviation [SD]) age was 50.5 (9.8) years and 63% were female. In the treatment period, almost every patient had at least 1 MS-related outpatient visit, 24% were hospitalized due to MS, and 79% utilized MS-specific physical therapy in addition to the fampridine treatment. Total MS-related healthcare costs were significantly higher in the fampridine treatment period than in the period prior to fampridine initiation (€17,392 vs €10,960, P < 0.001). While this difference was driven primarily by prescription costs, MS-related inpatient costs were lower during fampridine treatment (€1,333 vs €1,565, P < 0.001). Conclusions Physical therapy is mainly used concomitant to fampridine treatment. While healthcare costs were higher during fampridine treatment compared to the pre-treatment period, inpatient costs were lower. Further research is necessary to better understand the fampridine influence.http://link.springer.com/article/10.1186/s12883-017-0844-zMultiple sclerosisClaims dataGermanyFampridine |
| spellingShingle | Tjalf Ziemssen Christine Prosser Jennifer Scarlet Haas Andrew Lee Sebastian Braun Pamela Landsman-Blumberg Angela Kempel Erika Gleißner Sarita Patel Ming-Yi Huang Healthcare resource use and costs of multiple sclerosis patients in Germany before and during fampridine treatment BMC Neurology Multiple sclerosis Claims data Germany Fampridine |
| title | Healthcare resource use and costs of multiple sclerosis patients in Germany before and during fampridine treatment |
| title_full | Healthcare resource use and costs of multiple sclerosis patients in Germany before and during fampridine treatment |
| title_fullStr | Healthcare resource use and costs of multiple sclerosis patients in Germany before and during fampridine treatment |
| title_full_unstemmed | Healthcare resource use and costs of multiple sclerosis patients in Germany before and during fampridine treatment |
| title_short | Healthcare resource use and costs of multiple sclerosis patients in Germany before and during fampridine treatment |
| title_sort | healthcare resource use and costs of multiple sclerosis patients in germany before and during fampridine treatment |
| topic | Multiple sclerosis Claims data Germany Fampridine |
| url | http://link.springer.com/article/10.1186/s12883-017-0844-z |
| work_keys_str_mv | AT tjalfziemssen healthcareresourceuseandcostsofmultiplesclerosispatientsingermanybeforeandduringfampridinetreatment AT christineprosser healthcareresourceuseandcostsofmultiplesclerosispatientsingermanybeforeandduringfampridinetreatment AT jenniferscarlethaas healthcareresourceuseandcostsofmultiplesclerosispatientsingermanybeforeandduringfampridinetreatment AT andrewlee healthcareresourceuseandcostsofmultiplesclerosispatientsingermanybeforeandduringfampridinetreatment AT sebastianbraun healthcareresourceuseandcostsofmultiplesclerosispatientsingermanybeforeandduringfampridinetreatment AT pamelalandsmanblumberg healthcareresourceuseandcostsofmultiplesclerosispatientsingermanybeforeandduringfampridinetreatment AT angelakempel healthcareresourceuseandcostsofmultiplesclerosispatientsingermanybeforeandduringfampridinetreatment AT erikagleißner healthcareresourceuseandcostsofmultiplesclerosispatientsingermanybeforeandduringfampridinetreatment AT saritapatel healthcareresourceuseandcostsofmultiplesclerosispatientsingermanybeforeandduringfampridinetreatment AT mingyihuang healthcareresourceuseandcostsofmultiplesclerosispatientsingermanybeforeandduringfampridinetreatment |